Positive phase III results for Roche’s Gazyva/Gazyvaro show
WEB5 days ago · Gazyva®/Gazyvaro® (obinutuzumab) is a Type II engineered humanised monoclonal antibody designed to attach to CD20, a protein found on certain types of B cells. 1 In lupus nephritis, disease ...
Significant benefit seen with obinutuzumab in lupus nephritis trial
WEB9 hours ago · October 1, 2024. The trial met its primary endpoint showing a significant improvement in complete renal response with obinutuzumab with standard therapy vs standard therapy alone after 76 weeks ...
Positive Phase III Results for Genentech’s Gazyva Show Superiority …
WEB5 days ago · Gazyva® (obinutuzumab) is a prescription medicine used: With the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous CLL treatment.
UPDATE: Positive Phase III Clinical Trial Results Announced for …
WEB5 days ago · Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN). Gazyva is an engineered humanized monoclonal antibody designed to attack CD20, a protein found on certain types of B cells that cause inflammation and damage to the kidneys. Gazyva works to deplete disease-causing B cells to protect the kidney from ...
Genentech: Press Releases | Wednesday, Sep 25, 2024
WEBSep 25, 2024 · South San Francisco, CA -- September 25, 2024 --. Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase III REGENCY study of Gazyva ® (obinutuzumab) in people with active lupus nephritis. In the study, a higher proportion of people treated with Gazyva plus standard therapy ...
Gazyva® Shows Positive Results in Phase 3 Lupus Nephritis Trial
WEBSeptember 25, 2024. The Lupus Research Alliance (LRA) and clinical research affiliate Lupus Therapeutics (LT) are excited to share positive news of the Phase 3 REGENCY clinical trial showing benefits of Gazyva ® (obinutuzumab) in treating people with active lupus nephritis (inflammation of the kidney associated with lupus). In development as a potential treatment for lupus nephritis, Gazyva ...
Roche's Lupus Study for Gazyva Meets Primary & Key Secondary …
WEB6 days ago · ROG.SW. Roche RHHBY announced positive top-line data from a late-stage study of its marketed drug, Gazyva/Gazyvaro (obinutuzumab), to treat patients with active lupus nephritis (LN). The phase III ...
Roche Looks to Push Gazyva Into Lupus Nephritis With ... - BioSpace
WEB4 days ago · In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis versus placebo, positioning Roche’s therapeutic antibody for expansion into the indication. ... BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect ...
Positive Phase III results for Roche’s Gazyva/Gazyvaro in lupus
WEB1 day ago · Swiss pharma giant Roche has announced positive top-line results from the Phase III REGENCY study of Gazyva/Gazyvaro (obinutuzumab) in people with active lupus nephritis. ... Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. Updates from clinical trials, …
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting ...
WEBJun 4, 2019 · In this open-label, phase 3 trial, we investigated fixed-duration treatment with venetoclax and obinutuzumab in patients with previously untreated CLL and coexisting conditions.